Characterization of patients with basal cell carcinoma treated with HeberFERON at the "Amalia Simoni" Hospital in Camagüey, Cuba

Authors

  • Yudelys Montano Pérez Especialista de primer grado en Dermatología, Máster en atención integral a la mujer. Profesor Asistente. Hospital Clínico Quirúrgico Docente “Amalia Simoni”.
  • Beatriz Mantecón Fernández Especialista de segundo grado en Dermatología. Máster en enfermedades tropicales. Profesor Auxiliar. Hospital Clínico Quirúrgico Docente “Manuel Ascunce Domenech”.
  • Yenisey Gleidis Mir García Especialista de segundo grado en Dermatología y Especialista de segundo grado en Medicina General Integral. Máster en enfermedades infecciosas y en Educación Médica. Profesor Asistente. Investigador agregado. Hospital Clínico Quirúrgico Docente “Manuel Ascunce Domenech”.
  • Dainery Fernández Cervantes Especialista de primer grado en Dermatología y Especialista de primer grado en Medicina General Integral. Hospital Clínico Quirúrgico Docente “Manuel Ascunce Domenech”.
  • Rufina de los Milagros Pérez Castillo Licenciada en Educación primaria y licenciada en estudios socioculturales. Máster en Ciencias de la Educación Superior. Profesora Auxiliar. Universidad de Camagüey “Ignacio Agramonte y Loynaz”.

DOI:

https://doi.org/10.61997/bjm.v11i1.255

Keywords:

basal cell carcinoma, dermatology, cancer

Abstract

Introduction: Basal cell carcinoma is a relatively frequent malignant neoplasm in dermatological practice. Objective: To characterize patients with basal cell carcinoma treated with HeberFERON. Methods: a cross-sectional descriptive study was carried out from June 2018 to February 2020, with 88 patients treated with HeberFERON. Results: a predominance of the group of 70 to 79 years accounting 25 patients (28.4%) and the male sex with 47 cases (53.5%) was observed. Patients carrying lesions with high clinical risk for recurrence (78.4%) predominated. The largest number of patients were evaluated between 1 and 2 years after completion of treatment (42 cases). 98 % of the patients did not show recurrence, and the only one had it between 1 and 2 years after treatment. 98.9 % of the cases achieved good aesthetic results. Conclusions: on the evaluation performed between 1 and 2 years after the end of the treatment, almost all patients did not present recurrences and had good aesthetic results.

Downloads

Download data is not yet available.

Downloads

Published

17-10-2023

How to Cite

Montano Pérez, Y., Mantecón Fernández, B., Mir García, Y. G., Fernández Cervantes, D., & Pérez Castillo, R. de los M. (2023). Characterization of patients with basal cell carcinoma treated with HeberFERON at the "Amalia Simoni" Hospital in Camagüey, Cuba. Belize Journal of Medicine, 11(1), 14–20. https://doi.org/10.61997/bjm.v11i1.255

Issue

Vol. 11 No. 1 (2022): January-June

Section

Original

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

BJM protects Copyright at all times. However, it gives up part of the rights by displaying a Creative Commons License 4.0 (cc-by-nc), which allows the use of the work to share (copy and redistribute the material in any support or format) and adapt (transform and built from the material) as long as exclusive mention of the publication in the journal as the primary source is made. Under no circumstances, the work can be commercialized.